Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
← catalyst calendarNCT05489211 · readout in 407 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
454estimated
Sites
96
Countries
Canada, China, France +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-06 | actual | When the study began enrolling |
| Primary completion | 2027-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-01 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Endometrial Cancer
- Gastric Cancer
- Metastatic Castration-resistant Prostate Cancer
- Ovarian Cancer
- Colorectal Cancer
- Urothelial Cancer
- Biliary Tract Cancer
Interventions
- Drug: Datopotamab deruxtecan (Dato-DXd) — also filed as DS-1062a
- Drug: Capecitabine — also filed as Xeloda
- Drug: 5-Fluorouracil — also filed as Adrucil
- Drug: Volrustomig — also filed as MEDI5752
- Drug: Carboplatin — also filed as Paraplatin
- Drug: Bevacizumab — also filed as Avastin
- Drug: Rilvegostomig — also filed as AZD2936
- Drug: Prednisone/ prednisolone — also filed as Prednisolone
- Drug: Cisplatin — also filed as Platinol
Primary outcomes
what the primary-completion date above is the date OFObjective response rate (ORR)
measured From baseline to progressive disease or death (approximately 1 year)
The number of subjects with adverse events/serious adverse events
measured Throughout the treatment and the safety follow-up period 28 [+ 7] days after the discontinuation of all study interventions, except durvalumab, nivolumab, and bevacizumab for which it will be 90 [+ 7] days (approximately 1 year)
PSA50 response (Substudy 3 only)
measured From baseline to PSA response evaluated according to the PCWG3 criteria (approximately 1 year)
Progression free survival (PFS) response (Substudy 4C only)
measured From baseline to progressive disease or death (approximately 1 year)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed